Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases,...
May 20, 2024 16:16 ET | Source: Avalyn Pharma Inc.

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

AP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations...
May 13, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference

Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary Fibrosis Avalyn to be featured in ATS Mini Theater Program...
May 01, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases,...
March 06, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Leerink Partners Global Biopharma Conference

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
February 06, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
December 06, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference

SEATTLE, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
November 09, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis

Preclinical data that supported initiation of the completed Phase 1a AP02 inhaled nintedanib study to be presented for the first time at the PFF Summit AP01 inhaled pirfenidone clinical data,...
November 06, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
October 05, 2023 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right